That is a little deceptive, in which it assumes the production profile and LOM of the companies are the same.
I have not completed as much due diligence with NST as I have with RMS, but the total FCF of NST is significantly higher than that of RMS with current resource estimates hence a logical reason for the disparity in premium and conversion rate of those reserves to cash.
If they can proove that there is more ore than currently modeled and are able to increase the rate of capital conversion you would see the gap close significantly.
- Forums
- ASX - By Stock
- Broker Report March 2018
That is a little deceptive, in which it assumes the production...
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RMS (ASX) to my watchlist
|
|||||
Last
$1.97 |
Change
0.015(0.77%) |
Mkt cap ! $2.247B |
Open | High | Low | Value | Volume |
$2.00 | $2.01 | $1.95 | $9.599M | 4.870M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 87547 | $1.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.97 | 134610 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 1.955 |
3 | 14689 | 1.950 |
3 | 22629 | 1.945 |
5 | 12184 | 1.940 |
2 | 6420 | 1.935 |
Price($) | Vol. | No. |
---|---|---|
1.970 | 2298 | 2 |
1.980 | 5000 | 1 |
1.990 | 8920 | 2 |
1.995 | 3920 | 1 |
2.000 | 20744 | 5 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
RMS (ASX) Chart |